Down 50%, should you buy the dip on Pfizer?
Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments